Members, as well as health plans, pharmacy benefit managers, plan sponsors, and reinsurers want to know how to fund these expensive treatments to ensure positive outcomes.
Wes Smith, FSA, CERA, MAAA
Advertisement
Articles by Wes Smith, FSA, CERA, MAAA
Advertisement
Latest Updated Articles
Study: How Individual Carbohydrate Responses Reveal Metabolic Health and Potential BiomarkersPublished: June 12th 2025 | Updated: June 16th 2025
Department of Health and Human Services Reconstitutes ACIP, Removing 17 Sitting MembersPublished: June 10th 2025 | Updated: June 12th 2025
NLA 2025: Managing Omega-3 Therapy With Statins, PCSK9 Inhibitors for Cardiovascular CarePublished: June 2nd 2025 | Updated: June 11th 2025
ASCO 2025: Zongertinib Shows Strong Potential in HER2-Mutant NSCLC Treatment LandscapePublished: June 3rd 2025 | Updated: June 11th 2025
Emerging Data: Impacts of ROCKstar and AGAVE-201Published: May 30th 2025 | Updated: June 5th 2025
Measles Cases Climb to 800 in United States as Outbreak Spreads Across BordersPublished: April 18th 2025 | Updated: April 21st 2025
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
Effectively Managing Immunizations in the Long-Term Care Setting
2
Elranatamab Plus Daratumumab and Lenalidomide Yields Durable Responses, Manageable Safety
3
Creating a Culture of Quality in Fast-Melt Tablet Development
4
IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
5
